#David Mayhew CBE#stockbroking#JP Morgan#Alzheimer's

Alzheimer's Research UK welcomes new Chairman

David Mayhew CBE, former chairman of JP Morgan Cazenove, has this week been appointed Chairman of the Board of Trustees of Alzheimers Research UK, the ...

Admin
|Jul 5|magazine6 min read

David Mayhew CBE, former chairman of JP Morgan Cazenove, has this week been appointed Chairman of the Board of Trustees of Alzheimer’s Research UK, the UK’s leading dementia research charity.

Now Vice Chairman of JP Morgan’s global Investment Bank, Mayhew served as Chairman of the stockbrokers until November last year, and has built up a wealth of experience after more than 40 years with the company.

He officially took up his new role for Alzheimer’s Research UK at the Trustees’ meeting on July 3rdand is now part of the voluntary board; which plays an important strategic role in the charity’s development, overseeing its work and bringing together a wide range of expertise to help in its mission to defeat dementia.

To read the latest edition of Healthcare Global,  click here

Alzheimer’s Research UK is the UK’s leading charity specialising in finding preventions and new treatments for dementia, currently supporting 125 research projects worth over £18 million across the UK Mayhew will strive to help keep the research funding high on the political agenda.

 “I’m delighted to join Alzheimer’s Research UK in this role, and look forward to helping the charity grow and fulfil its mission,” the new Chairman stated.

“Dementia presents an enormous challenge to society, and at a cost of £23 billion a year to the UK economy, it is simply not a problem that can be ignored.

“The only way to tackle the growing challenge of dementia is through research, and I hope I can make a valuable contribution to help the charity achieve its aims.”

Shirley Cramer CBE, Chief Executive at Alzheimer’s Research UK, said: “We’re thrilled to have David joining us. Alzheimer’s Research UK is growing, and with his experience guiding the charity, I’m confident that we can become even more effective as we expand.

“If we are to offer hope to the 820,000 people affected by dementia in the UK, we need to see long-term, sustained investment in research, and this new appointment will be a great boost to help us achieve that goal.”